This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
- CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial
- The company also participated in the H.C. Wainwright BioConnect Conference earlier in January
- The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis
In addition to being moderated, investors and interested parties were given the opportunity to submit questions to Mr. Climaco during the live event. The conference also accepted pre-submitted questions before…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
Image sourced from Unsplash
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
